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Introduction: Lung cancer is the leading cause of cancer-related mortality. In patients with 
nonsquamous non-small-cell lung cancer (NSCLC) stage IIIB/IV treatment with chemotherapy 
plus bevacizumab led to significant improvements in progression-free and median overall 
survival (OS).
Aim: To report the experience of five Portuguese centers in treating patients with nonsquamous 
NSCLC in stage IIIB or IV with bevacizumab and chemotherapy regarding survival and toxicity 
outcomes.
Materials and methods: This was a retrospective, multicenter study on patients with 
  nonsquamous stage IIIB/IV NSCLC treated with bevacizumab and chemotherapy from 
  November 2007 to August 2010 through special use permits. We reviewed the medical records, 
registry of demographic characteristics, treatments provided, treatment responses, adverse events, 
and dates of death. Statistical analysis was performed with SPSS statistics software. Median OS 
and event-free survival (EFS) were calculated using the Kaplan–Meier method.
Results: From an eligible population of 41 patients, 37 participants were registered. Study 
participants were predominantly male (78.4%) with a median age of 53 years (29–75 years). 
In total, 83.8% patients had stage IV disease (TNM, 6th Ed.). The OS was 21.5 months (95% 
confidence interval [CI]: 12.6–30.5] and median EFS was 9.4 months (95% CI9: 7.1–11.7). 
Hematologic toxicity grade 3/4 occurred in 35.1% of patients, and nonhematologic toxicity in 
24.3% patients. One fatal thromboembolic event was recorded (2.7%).
Conclusions: The results of chemotherapy plus bevacizumab treatment for nonsquamous 
NSCLC obtained from the daily clinical practice of the centers involved in this study were 
similar to those of published clinical trials. Collaboration between the different Portuguese 
centers is crucial for this kind of study.
Keywords: lung neoplasms, carcinoma, non-small-cell lung, nonsquamous, bevacizumab, 
angiogenesis inhibitors
Introduction
Lung cancer is the most frequent cancer worldwide, with an estimated 1.61 million new 
cases in 2008 accounting for 12.7% of all new cancer patients.1 Moreover, lung cancer 
is the main cause of mortality by malignancy, resulting in 1.38 million deaths, that is, 
18.2% of total cancer mortality.1 Globally, the 5-year-survival rate is 15.6%.2
In Portugal, lung cancer is the third most common cancer in men (34.9/100,000), 
and has the fifth highest incidence when considering both sexes (20.1/100,000).3
At the time of diagnosis, three in every four patients (76.8%) have advanced or 
metastatic disease (46.9% in stage IV; TNM Classification of Malignant Tumors [TNM] 
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6th Edition). Around 87.5% of cases are non-small-cell 
lung cancers (NSCLC), with a predominance of non-
squamous types (57.0%).4 In patients diagnosed with stage 
IIIB/IV NSCLC without epidermal growth factor receptor 
(EGFR) mutations predictive of response to tyrosine kinase 
inhibitors, standard treatment relies on platinum-doublet 
chemotherapy (CT).
Over the last 20 years, survival in lung cancer patients has 
remained relatively constant,5 highlighting the need for new 
drugs to improve the prognosis of this disease. Bevacizumab 
is a novel drug reported to promote improvements in response 
and survival rates.6–9
Bevacizumab is a recombinant humanized monoclonal 
IgG1 antibody. The drug acts via selective binding and 
neutralization of vascular endothelial growth factor (VEGF), 
thus inhibiting angiogenesis.10,11 Two phase III clinical trials, 
E4599 of the Eastern Cooperative Oncology Group (ECOG) 
and AVAiL (Avastin in Lung, also called BO17704), 
focused on the efficacy and safety of bevacizumab plus CT 
in the treatment of advanced (stage IIIB/IV) or recurring 
NSCLC nonsquamous type.6–9 Both studies concluded 
that the administration of bevacizumab plus CT enhanced 
response rates (RR) and progression-free survival (PFS) with 
statistical significance. The E4599 clinical trial additionally 
showed a significant increase in overall survival (OS; 
12.3 m vs 10.3 m (hazard ratio [HR] 0.79; P = 0.003)) 
in patients treated with bevacizumab plus CT versus CT 
alone.6–9 Another phase III trial, AVAPERL (MO22089), 
investigating bevacizumab maintenance was presented at 
the 2011 European Multidisciplinary Cancer Congress.12 In 
the study, patients were treated with four cycles of cisplatin 
plus pemetrexed plus bevacizumab. Patients showing no 
progression after four treatment cycles were randomized 
to receive further treatment with bevacizumab alone or 
bevacizumab plus pemetrexed.12 The preliminary results of 
AVAPERL disclosed a significant improvement in PFS for 
patients subjected to maintenance treatment with pemetrexed 
plus bevacizumab (10.2 m; P , 0.001) versus bevacizumab 
alone (6.6 m).12
In 2006, the Food and Drug Administration (FDA) granted 
approval for bevacizumab administration in combination with 
carboplatin and paclitaxel for the treatment of unresectable, 
locally advanced, recurrent, or metastatic nonsquamous 
NSCLC.13 This treatment was implemented in some centers 
of the National Health System in Portugal through the 
implementation of special use permits (autorização de 
utilização especial [AUE]), until its refusal by the National 
Authority of Medicine and Health Products (INFARMED, 
Autoridade Nacional do Medicamento e Produtos de Saúde 
I.P.) in April 2010.14
In the current study, we evaluated the experience of 
five Portuguese centers that treated patients diagnosed with 
nonsquamous NSCLC stages IIIB and IV with chemotherapy 
plus bevacizumab under special use permits, and reported 
outcomes in terms of survival and toxicity.
Materials and methods
We conducted a multicenter retrospective study using 
available lung cancer treatment clinical registry data from 
five Portuguese centers, including the Portuguese Institute of 
Oncology of Oporto, Hospital S. João of Oporto, Vila Nova 
de Gaia – Espinho Medical Center, Faro Hospital, and the 
Hospital of Santa Maria – Lisbon North Hospitalar Center.
The eligible population was composed of adult patients 
diagnosed with nonsquamous NSCLC (histological or 
cytological), stage IIIB/IV, treated with chemotherapy 
plus bevacizumab under special use permits issued by 
INFARMED between November 2007 and August 2010. As 
a criterion for exclusion, we considered the impossibility of 
obtaining clinical information for individual patients.
The study included the following variables: (1)   demographic 
characteristics of the population, (2) t  reatment, (3)   effectiveness, 
and (4) safety.
1.  Demographic characteristics included diagnostic data 
(date of biopsy on the pathology report), pathological 
diagnosis, comorbidities, ECOG functional state and 
disease stage (TNM).
2.  Treatment included information about the therapeutic 
protocol, surgery and/or radiotherapy realization, and 
other treatments applied for second-line therapy and 
afterwards.
3.  Effectiveness variables included response after three 
cycles, and dates of progression and death.
4.  Safety involved a toxicity assessment according to the 
Common Terminology Criteria for Adverse Events 
(CTCAE; version 4.02) of the National Cancer Institute 
(NCI).
Statistical analysis was performed with the SPSS statistics 
program (v. 19; SPSS Inc, Chicago, IL). Absolute and 
relative frequencies were calculated for categorical variables. 
Continuous variables were assessed as follows: (1) for age, 
the median was calculated, (2) for event-free survival (EFS) 
and OS, analysis was performed using the Kaplan–Meier 
method considering the date of (a) first treatment, (b) event, 
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defined as progression of disease confirmed with imaging 
tests or death if no prior confirmation of progression, and 
(c) death.
Results
The eligible population consisted of 41 patients, four of 
whom were excluded owing to lack of clinical data. The 
participant population (n = 37) was mostly composed of male 
patients (78.4%) with a median age of 53 years (29–75 years). 
Eight patients were 65 years or older (21.6%) (Table 1). 
The majority of patients had adenocarcinoma (94.6%) 
and stage IV disease (83.8%). The ECOG performance status 
was 0 in 12 patients (32.4%) and 1 in 24 (64.9%) patients. 
Smoking (62.1%) and hypertension (16.2%) were the 
most frequent comorbidities. Three patients had a history 
of previous neoplasm, and two had hematologic diseases 
(polycythemia vera, idiopathic myelofibrosis).
Treatment at the Portuguese participant centers included 
the administration of bevacizumab (under special use permits 
issued by INFARMED) in combination with carboplatin 
and gemcitabine (59.5%) (Table 2). Bevacizumab was 
additionally administered with a platinum and paclitaxel 
(24.3%) or platinum and pemetrexed (8.1%) regimen. Only 
one patient was treated with 15 mg/kg of bevacizumab. 
The majority of patients were subjected to six cycles of 
CT (75.7%). During the time of data collection, 10 patients 
Table 1 Summary of key demographic characteristics
Variable Absolute frequency Relative frequency Other frequency measures
Age (years) 
  ,65 
  $65
 
29 
8
 
78.4% 
21.6%
 
Median 53 years (29; 75)
Sex 
  Male 
  Female
 
29 
8
 
78.4% 
21.6%
 
Median age 55 years (29; 75) 
Median age 48 years (42; 66)
Histologic type 
  Adenocarcinoma 
  Poorly differentiated carcinoma
 
35 
2
 
94.6% 
5.4%
Stage (TNM) 
  IIIB 
  IV
 
6 
31
 
16.2% 
83.8%
Comorbidities 
  Smoker 
  COPD 
  Tuberculosis 
  Alcoholism 
  Arterial hypertension 
  Diabetes mellitus 
  Dyslipidemia 
  Ischemic heart disease 
  Heart failure 
  Cerebrovascular disease 
  Previous cancer 
  –  Urothelial cancer 
  –  Prostate adenocarcinoma 
  –  Carcinoma in situ of the vocal cord 
Others 
  Neurofibromatosis 
  Psoriasis 
  Splenectomy 
  Hematologic diseases 
  –  Polycythemia vera 
  –  Idiopathic myelofibrosis
 
23 
4 
4 
2 
6 
1 
3 
1 
1 
1 
3 
1 
1 
1 
 
1 
1 
1 
 
1 
1
 
62.1% 
10.8% 
10.8% 
5.4% 
16.2% 
2.7% 
8.1% 
2.7% 
2.7% 
2.7% 
8.1% 
2.7% 
2.7% 
2.7% 
 
2.7% 
2.7% 
2.7% 
 
2.7% 
2.7%
ECOG performance status 
 0  
 1  
 2
 
12 
24 
1
 
32.4% 
64.9% 
2.7%
Abbreviations: COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; TNM, TNM Classification of Malignant Tumors, 6th Edition.
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Table 2 Treatment characteristics and patient status
Variable Absolute frequency Relative frequency
Chemotherapy regimen (plus bevacizumab)
  Platinum and paclitaxel 9 (cis 4; carbo 5) 24.3% (10.8%; 13.5%)
  Platinum and gemcitabine 25 (cis 3; carbo 22) 67.6% (8.1%; 59.5%)
  Platinum and pemetrexed 3 (cis 2; carbo 1) 8.1% (5.4%; 2.7%)
Number of chemotherapy cycles (first-line)
 # 3 4 10.8%
 4 3 8.1%
 5 2 5.4%
 6 28 75.7%
Bevacizumab dose
  7.5 mg/kg 36 97.3%
  15 mg/kg 1 2.7%
Number of bevacizumab cycles 
  #6 
  7–12 
  13–18 
  19–24 
  .24
 
10 
14 
9 
1 
3
 
27.0% 
37.8% 
24.3% 
2.7% 
8.1%
Second-line treatment 20 54.0%
  Pemetrexed 16 43.2%
  Erlotinib 3 8.1%
  Others 1 2.7%
Third-line treatment and further 7 18.9%
Patient status 
  Receiving first-line treatment 
  Alive with disease progression 
  Unknown 
  Death
 
10 
11 
1 
15
 
27.0% 
29.7% 
2.7% 
40.5%
Abbreviations: cis, cisplatin; carbo, carboplatin.
(27.0%) were still receiving first-line treatment. One of the 
patients was subjected to 26 administrations of bevacizumab, 
with good tolerance. Twenty patients received second-
line CT treatment, the majority with pemetrexed (n = 16). 
At the time of article preparation, fifteen deaths were 
recorded (40.5%).
The median OS was 21.5 months (95% confidence 
interval [CI]: 12.6–30.5) and median event-free survival was 
9.4 months (95% CI: 7.1–11.7) (Figure 1).
Thirteen patients (35.1%) displayed hematologic toxicity 
grade 3 or 4, with neutropenia as the most frequent adverse 
event (27.0%) (Table 3). Thrombocytosis was diagnosed in 
one patient (2.7%) with a previous history of splenectomy. 
Nonhematological toxicity of grade 3 or higher was 
reported for nine patients (24.3%), with a predominance 
of hypertension (10.8%), followed by hemoptysis (5.4%). 
One fatal thromboembolic event (2.7%) was recorded. 
It should be noted that at the time of data collection, a 
patient with polycythemia vera displayed good tolerance to 
14 administrations of bevacizumab.
Discussion
In the present study, the OS and EFS were 21.5 months 
(95% CI: 12.6–30.5) and 9.4 months (95% CI: 7.1–11.7), 
respectively. Overall, the treatment was well tolerated. 
There was a predominance of hematologic toxicity 
(grade 3 or higher) (35.1%) over nonhematological toxicity 
(24.3%).
Despite  the  limitations  regarding  the  design 
(a retrospective study with no control group and different 
treatment combinations), the results were consistent with 
those obtained in earlier phase III clinical trials with evidence 
level 1b (proposed by Oxford Centre for Evidence-Based 
Medicine).15 For statistical analysis, EFS was defined as 
progression of disease confirmed with imaging tests or 
death in case of no prior validation of progression, and used 
roughly as the equivalent of PFS. We propose that EFS is a 
better parameter definition for daily clinical practice and is 
almost equivalent to PFS for clinical trials, since the various 
centers do not have the image evaluation defined on time as 
in clinical trials.
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In the randomized E4599 study involving two groups 
(CT using carboplatin and paclitaxel [n = 444] or CT plus 
bevacizumab [n = 434]), increases in RR, PFS and OS were 
observed in the group treated with bevacizumab. RR was 
35% vs 15% (P , 0.001), PFS was 6.2 m vs 4.5 m (HR 0.66; 
95% CI: 0.57–0.77; P , 0.001) and OS was 12.3 m vs 
10.3 m (HR 0.79; 95% CI: 0.67–0.92; P = 0.003).6 Patients 
analyzed in this study had nonsquamous type NSCLC stage 
IIIB with pleural effusion, stage IV or recurrent disease, 
without previous administration of chemotherapy. Our study 
included four patients with stage IIIB disease without pleural 
effusion (N3 disease and no indication for radiotherapy), and 
therefore, longer survival times were expected. In the E4599 
study, 15 treatment-related deaths in the chemotherapy 
plus   bevacizumab group were reported, including five from 
pulmonary hemorrhage. There were no records of grade 5 
hemorrhage in our analysis, which may be attributable to the 
sample size or patient selection.
The AVAiL study included patients with stage IV and IIIB 
NSCLC with and without pleural effusion (supraclavicular 
lymph node metastasis) or with recurrent disease. This was 
a randomized study with three treatment groups, including: 
(1) CT with cisplatin and gemcitabine (n = 347), (2) CT plus 
low-dose bevacizumab -7.5 mg/kg (n = 345); (3) CT plus high-
dose bevacizumab -15 mg/kg (n = 351).8,9 The study had two 
major limitations: the primary goal was changed to PFS after 
implementation of the study, and the study did not provide 
statistical power for comparing the two doses of bevacizumab. 
The AVAiL study revealed a statistically significant increase 
in PFS in the two groups of patients treated with low and high 
doses of bevacizumab (HR 0.75; 6.7 m vs 6.1 m; P = 0.003), 
and (HR 0.82; 6.5 m vs 6.1 m; P = 0.03), respectively. 
A statistically significant increase in OS was observed. 
This may be due to the presence of confounding factors or 
inclusion of patients with characteristics predictive of better 
response to subsequent treatment lines. The median number 
of bevacizumab administrations was 5 and 6, respectively 
for high- and low-dose treatments. In our study, the median 
number of bevacizumab administrations was higher (nine). This 
may be due to the study design (as discussed above), presence 
of confounding factors in both studies, as well as different 
periodicities of imaging in clinical trials (every 8 or 9 weeks) 
and clinical practice in the community setting (usually after 
the third and sixth cycles of chemotherapy and 8 to 12 weeks 
thereafter). In the AVAiL study, the incidence of adverse effects 
(grade 3 or higher) was similar among all groups.
Table  3  Adverse  events  reported  during  treatment  with 
chemotherapy plus bevacizumab (grade 3 or higher) according to 
the Common Terminology Criteria for Adverse Events (version 4.02) 
of the National Cancer Institute
Adverse event Absolute  
frequency
Relative 
frequency
Hematologic 
  Anemia 
  Neutropenia 
  Thrombocytopenia 
  Thrombocytosis
13 
1 
10 
5 
1
35.1% 
2.7% 
27.0% 
13.5% 
2.7%
Nonhematologic 
  Arterial hypertension 
  Proteinuria 
  Hyponatremia 
  Renal failure 
  Thromboembolic event 
  Hemoptysis 
  Infection
9 
4 
0 
0 
1 
1 
2 
1
24.3% 
10.8% 
0.0% 
0.0% 
2.7% 
2.7% 
5.4% 
2.7%
None 20 54.1%
1.0
0.8
0.6
0.4
0.2
0.0
1.0
AB
0.8
0.6
0.4
0.2
0.0
0.0 0.05 .0 10.0 10.0 20.0 20.0 15.0 25.0 30.0 40.0
Event-free survival (months)
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
Overall survival (months)
Figure 1 Kaplan–Meier estimates of survival of 37 patients with nonsquamous NSCLC, stage IIIB/IV, treated with bevacizumab plus chemotherapy. (A) The median event-free 
survival was 9.4 months (95% CI: 7.1–11.7) and (B) median overall survival was 21.5 months (95% CI: 12.6–30.5).
Abbreviations: CI, confidence interval; NSCLC, non-small-cell lung cancer.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
95
Bevacizumab for lung cancer treatment in PortugalCancer Management and Research 2012:4
SAiL (Safety of Avastin in Lung; MO19390), a phase IV 
study involving 2212 patients,16 was performed with the main 
objective of assessing the safety of bevacizumab in everyday 
clinical practice. Severe toxicity, possibly related to bevaci-
zumab administration, was observed in 13% of the patients 
(n = 288). Adverse events, grade 3 or higher, of specific 
interest included: thromboembolic events in 172 patients 
(8%), hemorrhage in 4%, and gastrointestinal perforation 
in 1% patients (n = 27).
In  the  present  investigation,  we  observed  one 
  thromboembolic event of grade 3 or higher (2.7%; grade 5) 
and hemoptysis in two patients (5.4%). In the SAiL study, 
survival analysis was a secondary objective. The PFS was 
7.8 m (95% CI: 7.5–8.1) and median OS was 14.6 m (95% 
CI: 13.8–15.3). About 69% of patients (n = 525) showed 
disease progression, but no information was available about 
further treatments. In the current study, 20 patients (54.1%) 
received second-line treatment, mainly chemotherapy with 
pemetrexed (n = 16).
The AVAPERL study (MO22089) is an open-label phase 
III trial including 362 patients with advanced, metastatic or 
recurrent NSCLC.12 The preliminary data, presented at the 
2011 European Multidisciplinary Cancer Congress, revealed 
a significant improvement in PFS for patients subjected to 
maintenance treatment with pemetrexed plus bevacizumab 
(10.2 m; P , 0.001) versus bevacizumab only (6.6 m). EFS 
in our study was 9.4 months (95% CI: 7.1–11.7),12 which may 
be explained by the study design or selection of patients, as 
mentioned previously.
Conclusions
This study describes the experience of five centers in Portugal 
with chemotherapy plus bevacizumab treatment admin-
istered under Special Use Permits issued by INFARMED 
to patients with nonsquamous NSCLC, which appears 
similar to that described earlier in published phase III and 
IV studies.
In the study population obtained from our daily clinical 
practice, the addition of bevacizumab to standard chemo-
therapy did not increase or induce unexpected toxicity and 
improved survival, which may be attributed to the rigorous 
selection of patients.
In our opinion, it is important to publish the   Portuguese 
experience with novel drugs for lung cancer, and collaboration 
between different centers is crucial to achieve this aim.
Future studies should focus on the importance of 
predictive factors of response, evaluation of the quality of 
life, and pharmacoeconomic studies (cost minimization 
analysis: complete economic assessment with cost-benefit 
analysis, cost-effectiveness and cost-utility) in this group 
of patients.
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